These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26790689)

  • 1. Harm reduction as a complex adaptive system: A dynamic framework for analyzing Tanzanian policies concerning heroin use.
    Ratliff EA; Kaduri P; Masao F; Mbwambo JK; McCurdy SA
    Int J Drug Policy; 2016 Apr; 30():7-16. PubMed ID: 26790689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Today's fentanyl crisis: Prohibition's Iron Law, revisited.
    Beletsky L; Davis CS
    Int J Drug Policy; 2017 Aug; 46():156-159. PubMed ID: 28735773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles, practice, and policy vacuums: Policy actor views on provincial/territorial harm reduction policy in Canada.
    Hyshka E; Anderson-Baron J; Pugh A; Belle-Isle L; Hathaway A; Pauly B; Strike C; Asbridge M; Dell C; McBride K; Tupper K; Wild TC
    Int J Drug Policy; 2019 Sep; 71():142-149. PubMed ID: 30711412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Swiss drug policy change and the introduction of heroin maintenance treatment.
    Khan R; Khazaal Y; Thorens G; Zullino D; Uchtenhagen A
    Eur Addict Res; 2014; 20(4):200-7. PubMed ID: 24513780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harm Reduction Works: Evidence and Inclusion in Drug Policy and Advocacy.
    Klein A
    Health Care Anal; 2020 Dec; 28(4):404-414. PubMed ID: 33079317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cocaine and heroin markets in the era of globalisation and drug reduction policies.
    Costa Storti C; De Grauwe P
    Int J Drug Policy; 2009 Nov; 20(6):488-96. PubMed ID: 19447024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heroin-assisted treatment in Switzerland: a case study in policy change.
    Uchtenhagen A
    Addiction; 2010 Jan; 105(1):29-37. PubMed ID: 19922519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substances considered addictive: prohibition, harm reduction and risk reduction.
    Menéndez E
    Salud Colect; 2012; 8(1):9-24. PubMed ID: 23995492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do drug market changes affect characteristics of injecting initiation and subsequent patterns of drug use? Findings from a cohort of regular heroin and methamphetamine injectors in Melbourne, Australia.
    Horyniak D; Stoové M; Degenhardt L; Aitken C; Kerr T; Dietze P
    Int J Drug Policy; 2015 Jan; 26(1):43-50. PubMed ID: 25304048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-threshold methadone treatment, heroin price, police activity and incidence of heroin use: the Zurich experience.
    Nordt C; Stohler R
    Int J Drug Policy; 2009 Nov; 20(6):497-501. PubMed ID: 19349154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative analysis of transitions to heroin injection in Kenya: implications for HIV prevention and harm reduction.
    Guise A; Dimova M; Ndimbii J; Clark P; Rhodes T
    Harm Reduct J; 2015 Sep; 12():27. PubMed ID: 26337729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of research to Australian policy responses to heroin dependence 1990-2001: a personal retrospection.
    Hall W
    Addiction; 2004 May; 99(5):560-9. PubMed ID: 15078230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two steps forward, one step back: current harm reduction policy and politics in the United States.
    Nadelmann E; LaSalle L
    Harm Reduct J; 2017 Jun; 14(1):37. PubMed ID: 28606093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "It's Russian roulette": adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage.
    Harris M; Forseth K; Rhodes T
    Int J Drug Policy; 2015 Jan; 26(1):51-8. PubMed ID: 25444768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policy actor views on structural vulnerability in harm reduction and policymaking for illegal drugs: A qualitative study.
    Gehring ND; Speed KA; Wild TC; Pauly B; Salvalaggio G; Hyshka E
    Int J Drug Policy; 2022 Oct; 108():103805. PubMed ID: 35907373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug policy, intravenous drug use, and heroin addiction in the UK.
    Geraghty J
    Br J Nurs; 2011 Jul 28-Aug 4; 20(14):878-2, 884. PubMed ID: 21841676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of oral health policy in Nigeria: an analysis of the role of context, actors and policy process.
    Etiaba E; Uguru N; Ebenso B; Russo G; Ezumah N; Uzochukwu B; Onwujekwe O
    BMC Oral Health; 2015 May; 15():56. PubMed ID: 25943102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition to injection amongst opioid users in Iran: implications for harm reduction.
    Malekinejad M; Vazirian M
    Int J Drug Policy; 2012 Jul; 23(4):333-7. PubMed ID: 21996166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supply control policy, harm reduction and context dependence.
    Weatherburn D
    Addiction; 2005 Jul; 100(7):927-8; discussion 930-2. PubMed ID: 15955006
    [No Abstract]   [Full Text] [Related]  

  • 20. Muddling through policymaking: A complex adaptive systems perspective on policy changes in a free maternal and child healthcare program in Enugu State, Nigeria.
    Ogbuabor DC; Onwujekwe OE; Ezumah N
    Niger J Clin Pract; 2019 May; 22(5):682-691. PubMed ID: 31089024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.